2cureX's core technology, ChemoCellomics®, integrates synthesis of "high-value" compound libraries with high throughput screening (HTS) in primary cells from patients.
This unique drug discovery platform allows 2cureX to identify treatment regimens for the individual patient or novel drug candidates that are selected based on their efficacy against cancer cells whereas healthy cells from the same patients remain unaffected. Tumours and associated metastases develop over years and show considerable heterogeneity within and between patients. This heterogeneity is with the ChemoCellomics® technology matched with a corresponding dissimilar treatment offering.
The recent identification of cancer stem cells stresses the importance of accepting and exploiting the biological complexity at the outset of drug discovery